EUCTR2007-005021-30-IT进行中（未招募）不适用
TOP TRIAL. A RANDOMISED PHASE III CLINICAL TRIAL OF TRASTUZUMAB (HERCEPTIN) OPTIMIZATION IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST CANCER OVEREXPRESSING HER2 AFTER A FIRST LINE CHEMOTHERAPY PLUS TRASTUZUMAB - TOP TRIA
REGIONE LOMBARDIA - DIREZIONE GENERALE SANITA'0 个研究点开始时间: 2007年11月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- • >18 years of age. Patients older of 70 years of age are eligible on the basis of an individual risk-benefit assessment by the investigator Histologically confirmed breast cancer with locally advanced and/or metastatic disease Over expression of HER2 (3+) as determined by IHC or amplification of HER2/c-erbB2 by FISH/CISH of the primary tumour or of a metastasis Assessable disease. The presence of measurable disease is not needed for enrolment. Patients with bone lesions, ascites and pleural effusion as only sites of disease are considered eligible Completion of a first line chemotherapy in association with trastuzumab given for at least 6 months for advanced disease. The last dose of trastuzumab should have to be given within 6 weeks prior to randomisation for treatments given with a 3 weekly schedule or within 3 weeks if a weekly schedule was used (only for maintenance study) Progressive disease during or within 6 months from the completion of a first line chemotherapy plus trastuzumab for advanced disease or within 6 months from the completion of an adjuvant treatment for early disease (only for 2nd line study). Patients progressing more than 6 months after the completion of a first line trastuzumab-containing regimen should be re-treated with the previous regimen and included in 2nd line study after evidence of progression. Signed written informed consent obtained prior to any study specific study procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Women with locally advanced or metastatic breast cancer over expressing HER2 who have been previously treated with a first line chemotherapy plus trastuzumab. >18 years of age. Patients older of 70 years of age are eligible on the basis of an individual risk-benefit assessment by the investigator Histologically confirmed breast cancer with locally advanced and/or metastatic disease Over expression of HER2 (3+) as determined by IHC or amplification of HER2/c-erbB2 by FISH/CISH of the primary tumour or of a metastasis Assessable disease. The presence of measurable disease is not needed for enrolment. Patients with bone lesions, ascites and pleural effusion as only sites of disease are considered eligible Completion of a first line chemotherapy in association with trastuzumab given for at least 6 months for advanced disease. The last dose of trastuzumab should have to be given within 6 weeks prior to randomisation for treatments given with a 3 weekly schedule or within 3 weeks if a weekly schedule was used (only for maintenance study) Progressive disease during or within 6 months from the completion of a first line chemotherapy plus trastuzumab for advanced disease or within 6 months from the completion of an adjuvant treatment for early disease (only for 2nd line study). Patients progressing more than 6 months after the completion of a first line trastuzumab-containing regimen should be re-treated with the previous regimen and included in 2nd line study after evidence of progression. Signed written informed consent obtained prior to any study specific study procedures ECOG-PS >2 Pregnant or lactating women. Women of childbearing potential must implement adequate contraceptive measures Previous or current malignancies at other sites, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma of the skin, or other cancer curatively treated by surgery and with no evidence of disease for at least 5 years. Baseline LVEF <50% (measured by echocardiography or MUGA) performed within 4 weeks prior to randomisation. History of documented congestive heart failure, angina pectoris requiring antianginal medication, evidence of transmural infarction ECG, poorly controlled hypertension (systolic > 180 mmHg or diastolic > 100 mmHg); clinically significant valvular heart disease; high-risk uncontrolled arrhythmias Presence of CNS metastases, not amenable to curative therapy. Patients with previously treated CNS metastases must be asymptomatic and stable at radiological imaging from at least 3 months Patients with dyspnoea at rest due to malignant or other disease, or who require supportive oxygen therapy. Patients with pre-existing lung disease or advanced pulmonary involvement may be at increased risk of serious toxicities with trastuzumab and should be evaluated carefully before entry into the study Concomitant chemotherapy with anthracyclines, including liposomial drugs (only for 2nd line study) Treatment with any investigational drug within 30 days before beginning of enrolment in the trial History or presence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of trastuzumab
研究者
相似试验
进行中（未招募）
1 期
PHASE III CLINICAL TRIAL FOR THE EVALUATION OF THE EFFICACY AND SAFETY OF A PARACETAMOL + IBUPROFEN COMBINATION IN PATIENTS WITH mENSTRUAL PAIEUCTR2018-000138-37-ESaboratorios Farmalíder S.A.480
进行中（未招募）
不适用
RANDOMIZED PHASE III TRIAL OF PREOPERATIVE VERSUS POSTOPERATIVE CHEMOTHERAPY WITH CISPLATIN AND GEMCITABINE IN STAGE IB-IIIA NON-SMALL CELL LUNG CANCER NSCLC - POP 01eoadjuvant treatmento for early stage non small cell lung cancerMedDRA version: 9.1Level: LLTClassification code 10061873Term: Non-small cell lung cancerEUCTR2006-002708-33-ITISTITUTI FISIOTERAPICI OSPITALIERI
未知
不适用
A CLINICAL TRIAL PHASE III, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TO EVALUATE THE SAFETY AND EFFICACY OF MK-0431A (TAB OF A FIXED DOSE COMBINATION OF SITAGLIPTIN AND METFORMIN) IN PEDIATRIC PATIENTS WITH TYPE 2 DIABETES MELLITUSPER-117-11MERCK SHARP & DOHME PERU S.R.L.,
进行中（未招募）
不适用
PHASE III CLINICAL TRIAL TO ASSESS THE ADDED ROLE OF 68Ga-DOTANOC PET-CT IN PATIENTS WITH NEUROENDOCRINE TUMORS - NDneuroendocrine tumorsMedDRA version: 9.1Level: PTClassification code 10052399EUCTR2010-023827-34-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
未知
不适用
A PHASE III CLINICAL TRIAL TO STUDY THE TOLERABILITY AND IMMUNOGENICITY OF V503, A MULTIVALENT HUMAN PAPILOMAVIRUS (HPV) L1 VIRUS-LIKE PARTICICLE (VLP) VACCINE, IN 16- TO 26-YEAR-OLD MEN AND 16- TO 26-YEAR-OLD WOMEN.PER-105-12MERCK SHARP & DOHME PERU S.R.L.,200